Sheaff Brock Investment Advisors LLC Grows Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Sheaff Brock Investment Advisors LLC lifted its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 0.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 5,515 shares of the company’s stock after buying an additional 39 shares during the period. Sheaff Brock Investment Advisors LLC’s holdings in Medpace were worth $1,832,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Principal Securities Inc. increased its position in shares of Medpace by 25.7% during the fourth quarter. Principal Securities Inc. now owns 367 shares of the company’s stock worth $122,000 after purchasing an additional 75 shares in the last quarter. Vista Finance LLC acquired a new stake in shares of Medpace in the 4th quarter worth $346,000. Congress Asset Management Co. increased its position in Medpace by 14.7% during the 4th quarter. Congress Asset Management Co. now owns 53,696 shares of the company’s stock valued at $17,839,000 after buying an additional 6,878 shares in the last quarter. Rhumbline Advisers raised its stake in Medpace by 0.8% in the fourth quarter. Rhumbline Advisers now owns 73,320 shares of the company’s stock valued at $24,359,000 after buying an additional 581 shares during the last quarter. Finally, Arcus Capital Partners LLC acquired a new stake in Medpace in the fourth quarter worth about $321,000. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Down 0.7 %

Shares of MEDP opened at $340.17 on Friday. The company has a market capitalization of $10.57 billion, a price-to-earnings ratio of 29.79, a PEG ratio of 1.85 and a beta of 1.36. Medpace Holdings, Inc. has a 52 week low of $302.01 and a 52 week high of $459.77. The stock’s 50-day moving average price is $343.50 and its 200-day moving average price is $348.31.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 50.87% and a net margin of 17.66%. As a group, equities analysts anticipate that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Robert W. Baird increased their price objective on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Baird R W downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. William Blair reissued an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Finally, TD Cowen lowered their price target on Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $381.44.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.